Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy-Reference-Cited by-同舟云学术

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy

Published:2003-12 Issue:6 Volume:125 Page:1742-1749
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Lau George K.K,Yiu Harry H.Y,Fong Daniel Y.T,Cheng Hoi-Ching,Au Wing-Yan,Lai Lydia S.F,Cheung Micheal,Zhang Hai-Ying,Lie Albert,Ngan Roger,Liang Raymond

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference39 articles.

1. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers;Liang;J Clin Oncol,1999

2. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy—pathogenesis and management;Xunrong;Rev Med Virol,2001

3. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy;Hoofnagle;Ann Intern Med,1982

4. Acute flares in chronic hepatitis B;Perrillo;Gastroenterology,2001

5. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma;Clark;Ann Oncol,1998

Cited by 407 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab carries high risks of hepatitis B virus reactivation in hematologic and rheumatic patients with chronic or resolved hepatitis B;Journal of Gastroenterology and Hepatology;2024-08-24

2. Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis;Seminars in Oncology;2024-08

3. Impact of universal hepatitis B virus (HBV) screening using chemotherapy orders on the HBV reactivation in cancer patients;Supportive Care in Cancer;2024-07-24

4. Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan;Hepatology International;2024-02-20

5. Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy;Drug Safety;2024-02-14